Shares of MacroCure Ltd. (NASDAQ:MCUR) have received a consensus broker rating score of 3.00 (Hold) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.
Analysts have set a 12 month consensus price target of $1.50 for the company, according to Zacks. Zacks has also given MacroCure an industry rank of 111 out of 265 based on the ratings given to related companies.
Separately, Credit Suisse Group AG downgraded shares of MacroCure from a “neutral” rating to an “underperform” rating and set a $1.00 price objective for the company. in a report on Monday, July 18th.
An institutional investor recently raised its position in MacroCure stock. Renaissance Technologies LLC boosted its stake in shares of MacroCure Ltd. (NASDAQ:MCUR) by 25.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 186,500 shares of the company’s stock after buying an additional 37,700 shares during the period. Renaissance Technologies LLC owned 1.12% of MacroCure worth $166,000 at the end of the most recent quarter. 2.76% of the stock is currently owned by hedge funds and other institutional investors.
Shares of MacroCure (NASDAQ:MCUR) opened at 1.59 on Wednesday. MacroCure has a one year low of $0.75 and a one year high of $4.26. The company’s market capitalization is $28.16 million. The company’s 50-day moving average is $1.57 and its 200-day moving average is $1.33.
MacroCure Company Profile
MacroCure Ltd. is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MacroCure Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroCure Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.